The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Iovance Biotherapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose material adverse facts about the company's growth potential [1]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from May 9, 2024, to May 8, 2025, Iovance provided overly positive statements while concealing significant issues regarding its ability to meet demand for its treatments [1]. - Key factors contributing to the company's poor performance included maintenance that reduced capacity by over 50% for about one month, lower-than-expected Proleukin sales, and a variable pace in the initiation of treatments by approved treatment centers [1]. Financial Impact - Following the announcement of disappointing financial results and lowered revenue guidance on July 25, 2024, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in just one day [1]. Next Steps for Shareholders - Shareholders who purchased IOVA shares during the specified class period are encouraged to register for the class action by July 14, 2025, to potentially become lead plaintiffs and receive updates on the case [2]. Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements or omissions that artificially inflated stock prices [3].